STAT Plus: Pharmalittle: Roche plans aggressive SMA drug pricing; where are those clinical trial results?
Good morning. Elizabeth Cooney here in Boston while Ed Silverman hobnobs with industry types at the J.P. Morgan festivities in San Francisco. You can keep up with JPM news and analysis from STAT’s team of six reporters in our special Readout@JPM, which hits your inbox after 4 p.m. ET this week (sign up here for the Readout). Meanwhile, some news to fuel your morning.
For 20 years, the U.S. government has urged companies, universities, and other institutions that conduct clinical trials to record their results in a federal database, so doctors and patients can see whether new treatments are safe and effective. Few trial sponsors have consistently done so, a Science investigation shows, even after a 2007 law made posting mandatory. Reporting rates by most large pharmaceutical companies have improved sharply, but performance by many other trial sponsors, including NIH, was lackluster.
